# CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

> **NCT01848990** · PHASE4 · COMPLETED · sponsor: **Halozyme Therapeutics** · enrollment: 456 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Commercial Hylenex® recombinant (hyaluronidase human injection)
- **DRUG:** Precommercial Hylenex recombinant (hyaluronidase human injection)
- **DRUG:** Insulin lispro
- **DRUG:** Insulin aspart
- **DRUG:** Insulin glulisine

## Key facts

- **NCT ID:** NCT01848990
- **Lead sponsor:** Halozyme Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-02
- **Final completion:** 2014-09
- **Target enrollment:** 456 (ACTUAL)
- **Last updated:** 2018-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01848990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01848990, "CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01848990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*